CancerTYPE ID® is a molecular classification test that measures and integrates the expression of 92 genes in formalin-fixed paraffin embedded (FFPE) tumour samples and is able to classify 54 different tumour types to help identify the origin of cancers with unknown or uncertain primary site.
- Guides differential diagnosis and classification of the primary cancer site
- Aids selection of the most appropriate treatment regimen
CancerTYPE ID® is reimbursed by leading private medical insurance companies in the UK and is also available as a self-pay test in the NHS.
Tumour types classified by CancerTYPE ID®
CancerTYPE ID® classifies 54 different tumour types from FFPE samples.
KRAS and EGFR inhibitor drugs
CancerTYPE ID® is an excellent tool in aiding differential diagnosis between 2 or more possible cancer types.
Immunohistochemical (IHC) staining of CUP tumour samples can suggest the primary cancer type in some patients, but often it is not specific for a single tumour type (Greco et al). CancerTYPE ID® can help pinpoint the exact primary cancer type.
Treatment outcomes in patients with CUP of colorectal origin
A study by Hainsworth JD et al, 2011 describes the use of CancerTYPE ID® as an aid to select optimal therapy in CUP patients whose cancer was found to be of colorectal origin. The number of patients limited the power of the study, but the results were very encouraging:
- Site-directed 1st line therapy: 50% response rate, 8.5 month median progression-free survival
- Empirical 1st line CUP therapy: 17% response rate, and 6 month median progression-free survival
Median survival in patients receiving site-directed therapy was 27 months. This was similar to that reported for patients with metastatic colorectal cancer, and differs from the median survival of 8-11 months produced by current empirical regimens for CUP.
Diagnostic performance evaluation of CancerTYPE ID®
CancerTYPE ID has the most diagnostically comprehensive validation of a molecular classifier to date. Performance of CancerTYPE ID® (Erlander et al, Kerr et al) to classify 30 main tumour types and 54 subtypes:
- Sensitivity 87% for main cancer types
- Specificity 98-100%
- Positive predictive value (PPV) of 83% and negative predictive value (NPV) of 99%
- Provides a single molecular prediction in 74% of cases with two or more differential diagnoses
In an earlier study, the performance of CancerTYPE ID® was evaluated in CUP patients who had latent primary site clinically identified later in life (Greco et al):
- Included 20 metastatic cancer patients who had no detectable primary site of origin identified following standard clinical and pathologic – including IHC—workup, but who had a latent primary tumor site clinically identified later in life
- Tissue of origin predicted by CancerTYPE ID® was compared to the actual primary site identified clinically
- In 53% of the cases, CancerTYPE ID® prediction had the potential to change treatment
Integration of CancerTYPE ID® into the cancer classification process
CancerTYPE ID® is available exclusively from Lab 21 in the UK and Ireland. The test is performed at bioTheranostics, a CLIA and CAP accredited service laboratory located in San Diego, US.